“Still, the accelerated approval came as a surprise to many, given that Elevidys had failed the primary outcome in a Phase I study, unable to significantly improve patients’ functional performance versus placebo.”
What are you talking about Akki
”it showed improvements on many other levels”
can’t wait
What improvements on what levels?
you dig deep to cloud investor confidence
yet your sentiment is BUY
lol..
- Forums
- ASX - By Stock
- PER
- Clean insights and information easily found
Clean insights and information easily found, page-69
-
- There are more pages in this discussion • 89 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.1¢ |
Change
-0.002(2.41%) |
Mkt cap ! $73.92M |
Open | High | Low | Value | Volume |
8.1¢ | 8.2¢ | 8.0¢ | $38.56K | 476.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 136958 | 8.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.3¢ | 8178 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 136958 | 0.081 |
3 | 88252 | 0.080 |
2 | 212658 | 0.078 |
1 | 108571 | 0.077 |
2 | 85000 | 0.076 |
Price($) | Vol. | No. |
---|---|---|
0.083 | 8178 | 2 |
0.084 | 57142 | 1 |
0.085 | 90800 | 2 |
0.086 | 106100 | 2 |
0.087 | 65719 | 1 |
Last trade - 13.54pm 11/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |